Pharmacokinetics of Pirarubicin in Patients With Breast Cancer / 中国药房
China Pharmacy
;
(12): 352-353, 2001.
Artigo
em Chinês
| WPRIM
| ID: wpr-410268
ABSTRACT
AIM: To estabish a HPLC assay for the determination of pirarubicin(Pir) in plasma.METHODS: Daunomycin(DM) was used as the internal standard.Plasma samples were extracted with CHCl3∶ CH3OH(2∶ 1) .0.4M NH4Cl buffer(pH=9.0) solution: CH2OH(1∶ 9) and the internal standard were added.Separation was carried out on a 250mm× 4.6mm(5μ m) phenomenex column with 0.04M KH2PO4(pH=3.0) ∶ CH3CN(68∶ 32) as mobile phase.Fluorescent detector was set at an excitation wavelength of 480nm and an emission wavelength of 550nm.RESULTS: The calibration curves for serum Pir was linear over the range of 5~1 000ng/ml(r=0.9 997) .The recovery of Pir was 95.3% .The within-day and between-day variations were less than 5% .T1/2β , CLs, Vd and AUC of Pir were(12.8± 5.9) h, (128.3± 52.6) L/(m2· h) , (1 754.3± 478.2) L/m2 and (428.7± 137.2) ng/(h· ml) , respectively.CONCLUSION: The method is suited for monitoring blood concentration and pharmacokinetic study of Pir.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
China Pharmacy
Ano de publicação:
2001
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS